Physician profile
Rachel E Sheiman
NPI 1801808373
$2,204.87
in general payments reported to CMS, 2019-2025
21 companies · $421 in 2025
The $421 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $111 · 2021: $97.06 · 2022: $212 · 2023: $630 · 2024: $500 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $553.54 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $220.80 | 2019-2024 | Bexsero |
| Sanofi Pasteur INC. | $203.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $159.84 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Tris Pharma INC | $152.93 | 2019-2025 | Dyanavel Xr |
| Verrica Pharmaceuticals INC. | $140.65 | 2023 | Ycanth |
| Kaleo, INC. | $138.23 | 2020-2024 | Auvi-Q |
| Supernus Pharmaceuticals, INC. | $125.35 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $121.86 | 2020-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $82.01 | 2019-2022 | |
| Pfizer INC. | $78.13 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $48.09 | 2025 | Jornay Pm |
| Qol Medical, LLC | $27.55 | 2023 | Sucraid |
| Neos Therapeutics, LP | $26.16 | 2019-2023 | Adzenys Xr-Odt |
| Hologic Sales and Service, LLC | $24.65 | 2024 | Aptima |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $20.02 | 2023 | Methylphenidate Hydrochloride |
| Alexion Pharmaceuticals, INC. | $18.99 | 2024 | Koselugo |
| Genentech USA, INC. | $17.92 | 2020 | |
| Sobi, INC | $16.15 | 2019 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Adlon Therapeutics L.P. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Sheiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.